Azithromycin is used widely in clinical practice and recently it is available in
topical solution for ophthalmic use. The purpose of the current publication is
to summarize the newest information on azithromycin’s clinical usefulness over
ocular diseases. A PubMed (National Library of Medicine) and a ScienceDirect
search was conducted using the key phrases ‘azithromycin’, ‘meibomian’,
‘blepharitis’, ‘trachoma’, ‘toxoplasmosis’ from 2010 to 2017. Articles were
limited to articles published in English or at least having an English abstract.
There were no restrictions on age, ethnicity, or geographic locations of
patients. Topical azithromycin was found effective and safe in various ocular
surface infections, in meibomian gland dysfunction and in trachoma. Also, it may
substitute fluoroquinolones in corneal UV cross-linking. The World Health
Organization targets for trachoma elimination are being reached only after 3
years of annual mass drug administration. Oral azithromycin can participate in
combination regiments for toxoplasmosis, mainly because of its very good safety
profile and may play a significant role in toxoplasmosis in pregnancy.
Azithromycin is one of the safest antibiotics, well tolerated, and with special
pharmacokinetic properties. Also, it is characterized by a broad antimicrobial
spectrum. Azithromycin is efficacious for the treatment of a lot of ocular
diseases and may be included as monotherapy or in combination therapy in new
treatment protocols for more ocular infections. However, more research is needed
to determine this.
Background:We describe a case where hyperviscosity retinopathy and immunogammopathy maculopathy were the presenting features of IgA multiple myeloma and report the response of maculopathy to intravitreal injection of dexamethasone implants.Case presentation:A 56-year-old man presented at the Department of Ophthalmology with the chief complain of reduced vision for the past 10 days in both eyes. Ophthalmic examination revealed central retinal vein occlusion resembling signs with severe macular edema in both eyes with prominent serous macular detachment. After comprehensive evaluation, an IgA type kappa multiple myeloma was diagnosed complicated with hyperviscosity-associated retinopathy and immunogammopathy maculopathy. Patient was treated with multiple sessions of plasmapheresis, systemic chemotherapy, and finally intravitreal implants of dexamethasone with complete restoration of macular edema and serous macular detachment in both eyes. The visual function and the hyperviscosity-associated retinopathy were partially restored.Conclusion:Ocular manifestation might be the only presenting sign of a life-threatening disease such as IgA multiple myeloma. A high level of suspicion is required to diagnose and treat such cases promptly and effectively.
Purpose: Treatment with intravitreal injections of anti-vascular endothelial growth factor agents has been associated with an increased risk of arterial thromboembolic events. The aim of the present pilot study was to assess the effect of a single intravitreal injection of aflibercept on coagulation. Methods: Treatment-naïve patients with age-related macular degeneration (n = 47), who were scheduled to undergo treatment with intravitreal injections of aflibercept, were enrolled. None of the included patients received any anticoagulation therapy or had a history of a recent arterial thromboembolic event. Blood samples were collected before the first intravitreal injection, and at 7 and 30 days after aflibercept administration. We evaluated coagulation parameters, such as platelet count and plasma fibrinogen and D-dimer levels; functional clotting parameters, such as prothrombin time, international normalized ratio, and activated partial thromboplastin time; and anticoagulant parameters, such as the levels of Proteins S and C. Results: The levels of all of the evaluated biomarkers were within the normal range at baseline and at both the time points throughout the study. No statistically significant changes were observed in any of the measured parameters at 1 week and 1 month after aflibercept administration. Conclusion: A single intravitreal injection of aflibercept in treatment-naïve patients with exudative age-related macular degeneration has no statistically significant effect on blood coagulation parameters for up to 1 month after aflibercept administration. Our results also provide an explorative statistical data, and further studies are required to evaluate any significant clinical effects of aflibercept on blood coagulation parameters. ClinicalTrials.gov ID: NCT03509623.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.